{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:44:19Z","timestamp":1762332259268,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-53-01"],"award-info":[{"award-number":["ANR-10-LABX-53-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009469","name":"Conseil R\u00e9gional du Centre-Val de Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejpb.2023.12.003","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T19:01:47Z","timestamp":1702234907000},"page":"114163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies"],"prefix":"10.1016","volume":"195","author":[{"given":"Timoth\u00e9e","family":"Blin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Guillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youenn","family":"Jouan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Allouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Boursin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxane","family":"Domain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"S\u00e9cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Heuz\u00e9-Vourc'h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Forum of International Respiratory Societies, The Global Impact of Respiratory Disease, 2021. https:\/\/www.firsnet.org\/images\/publications\/FIRS_Master_09202021.pdf.","key":"10.1016\/j.ejpb.2023.12.003_b0005"},{"key":"10.1016\/j.ejpb.2023.12.003_b0010","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1073\/pnas.75.10.5071","article-title":"Asymmetric budding of viruses in epithelial monlayers: a model system for study of epithelial polarity","volume":"75","author":"Rodriguez Boulan","year":"1978","journal-title":"PNAS"},{"doi-asserted-by":"crossref","unstructured":"A. Mayor, A. Chesnay, G. Desoubeaux, D. Ternant, N. Heuz\u00e9-Vourc\u2019h, T. S\u00e9cher, Therapeutic antibodies for the treatment of respiratory tract infections\u2014current overview and perspectives, 2021.","key":"10.1016\/j.ejpb.2023.12.003_b0015","DOI":"10.3390\/vaccines9020151"},{"key":"10.1016\/j.ejpb.2023.12.003_b0020","article-title":"Therapeutic antibodies: a new era in the treatment of respiratory diseases?","author":"S\u00e9cher","year":"2018","journal-title":"Therapeutic Antibodies"},{"unstructured":"US Food and Drug Administration, Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products, 2023. https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/emergency-use-authorizations-drugs-and-non-vaccine-biological-products.","key":"10.1016\/j.ejpb.2023.12.003_b0025"},{"key":"10.1016\/j.ejpb.2023.12.003_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179763","article-title":"Evolution of anti-SARS-CoV-2 therapeutic antibodies","volume":"23","author":"Almagro","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.12.003_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejpb.2023.12.003_b0040","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2023.12.003_b0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0050","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Leyva-Grado","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.12.003_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2016.05.018","article-title":"Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin","volume":"234","author":"Respaud","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.12.003_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108022","article-title":"Therapeutic antibodies \u2013 natural and pathological barriers and strategies to overcome them","volume":"233","author":"Al Ojaimi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2023.12.003_b0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JIR.S234710","article-title":"Human neutrophil elastase proteolytic activity in ulcerative colitis favors the loss of function of therapeutic monoclonal antibodies","volume":"13","author":"Curciarello","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.ejpb.2023.12.003_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194843","article-title":"Human cysteine cathepsins degrade immunoglobulin g in vitro in a predictable manner","volume":"20","author":"Hoglund","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.12.003_b0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance \u2013 analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.ejpb.2023.12.003_b0080","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1021\/mp3005403","article-title":"Quantification and structure elucidation of in vivo bevacizumab modification in rabbit vitreous humor after intravitreal injection","volume":"9","author":"Chu","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.003_b0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/path.5221","article-title":"Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential","volume":"247","author":"Potey","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fcimb.2017.00160","article-title":"With friends like these: the complex role of neutrophils in the progression of severe pneumonia","volume":"7","author":"Pechous","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.615959","article-title":"The role of neutrophils and neutrophil elastase in pneumococcal pneumonia","volume":"11","author":"Domon","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nri1841","article-title":"Neutrophil serine proteases: specific regulators of inflammation","volume":"6","author":"Pham","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1183\/09031936.00215114","article-title":"Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence","volume":"46","author":"Guillon","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2023.12.003_b0110","doi-asserted-by":"crossref","first-page":"2003755","DOI":"10.1183\/13993003.03755-2020","article-title":"Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia","volume":"57","author":"Seren","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2023.12.003_b0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2022.11.006","article-title":"Inhaled IgG1 antibodies: the buffering system is an important driver of stability during mesh-nebulization","volume":"181","author":"Mayor","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.12.003_b0120","doi-asserted-by":"crossref","first-page":"31777","DOI":"10.1074\/jbc.M114.591339","article-title":"New selective peptidyl di(chlorophenyl) phosphonate esters for visualizing and blocking neutrophil proteinase 3 in human diseases","volume":"289","author":"Guarino","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2023.12.003_b0125","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/bcr3240","article-title":"A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy","volume":"14","author":"Fan","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2023.12.003_b0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2020.00168","article-title":"The proteolytic cleavage of therapeutic monoclonal antibody hinge region: more than a matter of subclass","volume":"11","author":"Deveuve","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0135","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nprot.2008.63","article-title":"Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates","volume":"3","author":"Korkmaz","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2023.12.003_b0140","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1440-1843.2008.01283.x","article-title":"Neutrophil elastase activity in acute lung injury and respiratory distress syndrome","volume":"13","author":"Hashimoto","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.ejpb.2023.12.003_b0145","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1165\/ajrcmb.20.4.3371","article-title":"Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum","volume":"20","author":"Witko-Sarsat","year":"1999","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115996","article-title":"Protease-Antiprotease Imbalance in Bronchiectasis","volume":"22","author":"Oriano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.12.003_b0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1432-1033.1982.tb19757.x","article-title":"Characterization of the binding domains in the fragments cleaved by cathepsin G from human plasma fibronectin","volume":"123","author":"Vartio","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejpb.2023.12.003_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7090244","article-title":"Proteases and their inhibitors in chronic obstructive pulmonary disease","volume":"7","author":"Dey","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2023.12.003_b0165","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2174\/1381612811319060002","article-title":"Selective inhibitors of human neutrophil proteinase 3","volume":"19","author":"Korkmaz","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejpb.2023.12.003_b0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/pr.115.012104","article-title":"Inhibitors and antibody fragments as potential anti-inflammatory therapeutics targeting neutrophil proteinase 3 in human disease","volume":"68","author":"Korkmaz","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2023.12.003_b0175","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.molimm.2007.10.043","article-title":"Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid","volume":"45","author":"Ryan","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-3083.1982.tb00750.x","article-title":"Cleavage of the four human IgG subclasses with cathepsin G","volume":"16","author":"Baici","year":"1982","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0185","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-3083.1980.tb00039.x","article-title":"Kinetics of the different susceptibilities of the four human immunoglobulin G subclasses to proteolysis by human lysosomal elastase","volume":"12","author":"Baici","year":"1980","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4161\/mabs.3.6.18119","article-title":"The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge","volume":"3","author":"Brezski","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.ejpb.2023.12.003_b0195","doi-asserted-by":"crossref","first-page":"30843","DOI":"10.1074\/jbc.M113.486142","article-title":"Engineered protease-resistant antibodies with selectable cell-killing functions","volume":"288","author":"Kinder","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2023.12.003_b0200","doi-asserted-by":"crossref","first-page":"17371","DOI":"10.1073\/pnas.0407965101","article-title":"Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG","volume":"101","author":"Wenig","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.ejpb.2023.12.003_b0205","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4161\/mabs.2.3.11780","article-title":"Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?","volume":"2","author":"Brezski","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.ejpb.2023.12.003_b0210","doi-asserted-by":"crossref","first-page":"L185","DOI":"10.1152\/ajplung.00085.2006","article-title":"Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines","volume":"292","author":"Candiano","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: new insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog Dis."},{"key":"10.1016\/j.ejpb.2023.12.003_b0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13058-018-0972-4","article-title":"Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo","volume":"20","author":"Hsiao","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2023.12.003_b0225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0230","doi-asserted-by":"crossref","first-page":"e00052","DOI":"10.1128\/JVI.00052-20","article-title":"Airway delivery of anti-influenza monoclonal antibodies results in enhanced antiviral activities and enables broad-coverage combination therapies","volume":"94","author":"Vigil","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2023.12.003_b0235","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.1002\/cti2.1460","article-title":"Assessment of antibodies in the upper and lower human respiratory tract at steady state and after respiratory viral infection","volume":"12","author":"Koutsakos","year":"2023","journal-title":"Clin Transl Immunology."},{"key":"10.1016\/j.ejpb.2023.12.003_b0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:38:53Z","timestamp":1762331933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"alternative-id":["S0939641123003272"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114163"}}